Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost. (ATOS)
A 12-month Prospective Observational Study Assessing the Real-world Clinical Effectiveness, Safety and Health-economic Benefits of Toujeo® Initiation After Oral Antidiabetic Drug Failure in Insulin-naïve Patients With Type 2 Diabetes Mellitus
Sponsor: Sanofi
This observational or N/A phase trial investigates Diabetes and is currently completed. Sanofi leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Dec 2025 — Present [monthly]
Completed
-
Nov 2025 — Dec 2025 [monthly]
Completed
-
Oct 2025 — Nov 2025 [monthly]
Completed
-
Sep 2025 — Oct 2025 [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
▶ Show 7 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
May 2022 — Jul 2024 [monthly]
Completed
-
Jan 2021 — May 2022 [monthly]
Completed
-
Apr 2020 — Jan 2021 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Mar 2019 — Apr 2020 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Dec 2018 — Mar 2019 [monthly]
Recruiting
-
Nov 2018 — Dec 2018 [monthly]
Recruiting
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .